Global Innovative Biologics and Biosimilars Market Growth (Status and Outlook) 2025-2031

The global Innovative Biologics and Biosimilars market size is predicted to grow from US$ 465450 million in 2025 to US$ 780800 million in 2031; it is expected to grow at a CAGR of 9.0% from 2025 to 2031.

Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) products.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Innovative Biologics and Biosimilars Industry Forecast” looks at past sales and reviews total world Innovative Biologics and Biosimilars sales in 2024, providing a comprehensive analysis by region and market sector of projected Innovative Biologics and Biosimilars sales for 2025 through 2031. With Innovative Biologics and Biosimilars sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Innovative Biologics and Biosimilars industry.

This Insight Report provides a comprehensive analysis of the global Innovative Biologics and Biosimilars landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Innovative Biologics and Biosimilars portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Innovative Biologics and Biosimilars market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Innovative Biologics and Biosimilars and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Innovative Biologics and Biosimilars.

This report presents a comprehensive overview, market shares, and growth opportunities of Innovative Biologics and Biosimilars market by product type, application, key players and key regions and countries.

Segmentation by Type:
Monoclonal Antibodies
Interferon
Insulin
Vaccines
Others

Segmentation by Application:
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Amgen
AbbVie
Sanofi
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Biogen
Celltrion
Sobi
3SBIO
Changchun High Tech
Kanghong Pharma
Innovent Biologics
Gan&Lee
Tonghua Dongbao
United Laboratory

Please note: The report will take approximately 2 business days to prepare and deliver. Show more